Why Your GLP-1 Prescription Was Denied (Even When It's Medically Necessary)

Insurance denials for GLP-1 medications have become one of the biggest barriers to evidence-based obesity care. Here's what's actually happening—and what both patients and clinicians can do about it.

If you're a patient who has been told you "need to lose weight" for years, finally found a treatment that works, and then discovered your insurance won't cover it, you're not alone.

If you're a physician who spends hours writing prior authorizations and appeals only to receive another denial, you're not imagining things either.

Over the past several years, insurance companies have dramatically expanded restrictions on GLP-1 medications—including semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®)—despite an explosion of evidence showing that these medications improve not only weight, but diabetes, cardiovascular disease, obstructive sleep apnea, chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), and overall mortality.

The frustrating part?

Many denials have little to do with whether the medication is medically appropriate.

The insurance landscape changed almost overnight

Several recent studies paint a striking picture. Between 2023 and 2025, Medicare Part D plans rapidly expanded prior authorization requirements for GLP-1 medications. What had been required by fewer than 15% of plans in 2023 became nearly universal by 2025. At the same time, patient cost-sharing increased substantially as many plans shifted from fixed copays to percentage-based coinsurance, dramatically increasing monthly out-of-pocket costs.

Even more striking is what plans choose to cover. Medicare covers diabetes indications for semaglutide and tirzepatide through the vast majority of Part D plans, yet coverage remains essentially nonexistent when the exact same medication is prescribed for FDA-approved obesity-related indications such as obesity itself or obstructive sleep apnea.

In other words: the medication isn't being denied because it doesn't work; it's being denied because of how the insurance benefit was designed.

A denial isn't always a medical decision

One of the biggest misconceptions is that every denial means an insurance company believes the medication is unnecessary. That's often not true. There are two fundamentally different reasons a GLP-1 prescription may be denied.

1. The medication is excluded from the benefit.

This is especially common for anti-obesity medications.

Many employer-sponsored plans simply exclude weight-loss medications altogether. Medicare Part D has historically excluded medications prescribed solely for weight loss because of federal statute—not because of medical evidence.

If the medication is excluded, writing a longer appeal letter usually doesn't change the outcome.

This is primarily a policy problem, not a medical one.

2. The medication is covered—but the insurer says you haven't met its requirements.

These denials usually involve:

• Prior authorization

• Step therapy

• Documentation requirements

• Dose restrictions

• Reauthorization criteria

• Diagnosis mismatch

  
  

These denials are often appealable. The key is knowing which type of denial you're dealing with before spending hours writing another medical necessity letter.

The rise of non-clinical barriers

Increasingly, insurers are adding requirements that go far beyond confirming that a medication is appropriate. These requirements often function less like medical review and more like administrative barriers designed to reduce utilization.

"Complete six months of Wellvolution first."

Many insurers now require participation in proprietary lifestyle programs—such as Wellvolution—before approving GLP-1 therapy. At first glance, this sounds reasonable. Lifestyle modification is important, but there's an important distinction. Current obesity guidelines recommend behavioral treatment and medication together, not one followed by the other after an arbitrary waiting period.

Requiring six months of an insurer-selected commercial program raises several concerns.

It may:

• Duplicate treatment the patient has already completed with their own physician, dietitian, therapist, or diabetes educator.

• Delay treatment for a progressive chronic disease.

• Disproportionately disadvantage patients with disabilities, caregiving responsibilities, demanding work schedules, limited internet access, or prior negative experiences with weight-loss programs.

• Ignore the reality that many patients have already spent years attempting lifestyle interventions before seeking medication.

  
  

Perhaps most importantly, there is little published evidence demonstrating that requiring a specific proprietary six-month program improves outcomes compared with clinician-directed obesity care.

"Your doctor isn't ABOM certified."

Some insurers have begun requiring obesity medications to be prescribed by physicians with certification from the American Board of Obesity Medicine (ABOM). ABOM certification is an excellent credential that reflects additional expertise in obesity medicine. It is not, however, a requirement for medical licensure or board certification.

Many highly experienced physicians—including family physicians, internists, pediatricians, and even endocrinologists—are not ABOM-certified.

That's because ABOM certification requires:

• Additional obesity-specific continuing medical education

• A separate certification examination

• Significant financial cost

• Time away from clinical practice

• Ongoing maintenance requirements

  
  

Many physicians who safely prescribe GLP-1 medications every day have never pursued this voluntary credential—not because they lack expertise, but because they lack the time, money, or protected educational leave to obtain it. If a patient meets FDA criteria, the medication is appropriate, and a board-certified physician is prescribing within their scope of practice, denying treatment solely because that physician lacks a voluntary certification becomes difficult to justify from a patient-care perspective. Importantly, there is little published evidence that restricting prescribing to ABOM diplomates improves safety or outcomes.

These barriers disproportionately affect the patients who need treatment most

Administrative hurdles are never distributed equally. Patients with stable employment, flexible schedules, transportation, reliable internet, and financial resources often find ways through. Others don't. Every additional form, required appointment, mandatory program, or appeal disproportionately affects patients who already face barriers to care.

Researchers have increasingly raised concerns that expanding prior authorization requirements may widen existing health disparities by delaying treatment for patients at highest cardiometabolic risk.

What physicians can do

Although clinicians cannot change benefit design, we can make the process more effective.

First, identify the actual denial reason.

Never accept "denied" as sufficient information. Obtain the actual denial letter.

Determine whether the problem is:

• Benefit exclusion

• Missing documentation

• Prior authorization criteria

• Step therapy

• Quantity limits

• Diagnosis mismatch

• Administrative error

  
  

Every one of these requires a different response.

Document prospectively.

Rather than reconstructing the chart after a denial, include common prior authorization requirements during the initial visit:

• BMI and weight trend

• Weight-related complications

• Previous medications

• Prior lifestyle interventions

• Contraindications

• Functional impairment

• FDA-approved indication

• Planned follow-up

• Percentage of body weight lost while on therapy if applicable

  
  

Specific documentation saves time later.

Appeal the actual reason—not obesity in general.

The strongest appeal directly addresses every criterion the insurer says wasn't met.

Instead of explaining why GLP-1 medications are effective, explain exactly where the patient's documentation satisfies the insurer's own policy.

Sometimes the appeal should challenge the policy itself

When an insurer requires six months of a proprietary lifestyle program, consider asking:

• What evidence supports this exact requirement?

• Why is previous clinician-directed treatment insufficient?

• Can prior participation satisfy the requirement?

• Can participation occur concurrently with medication?

• Is a disability accommodation available?

  
  

Similarly, if ABOM certification is required:

• Request the exact written policy.

• Ask whether board-certified endocrinologists, family physicians, internists, or obesity specialists without ABOM certification qualify.

• Request the evidence showing that the requirement improves patient safety.

• Ask how patients are expected to obtain care if no qualifying clinician is reasonably available.

  
  

These are reasonable questions. The burden should be on the insurer to demonstrate that additional restrictions improve patient outcomes—not simply reduce utilization.

The bigger issue

Physicians should absolutely continue advocating for individual patients.

But increasingly, this has become a systems problem rather than an individual documentation problem.

Professional organizations have begun calling for:

• Transparent prior authorization criteria

• Elimination of unsupported step therapy requirements

• Coverage consistent with FDA-approved indications

• Recognition of obesity as a chronic disease

• Continuity protections for patients already benefiting from therapy

• Reduced administrative burden

• Public reporting of denial and appeal rates

• Coverage decisions based on evidence rather than arbitrary administrative barriers

  
  

The bottom line

GLP-1 medications are among the most effective treatments ever developed for obesity and related metabolic disease. The challenge is no longer simply determining who would benefit. Increasingly, it's determining who can actually get access. Patients deserve coverage decisions based on medical evidence—not unnecessary administrative obstacles.

Physicians should continue writing strong documentation and thoughtful appeals, but we should also recognize when the problem isn't our charting. Sometimes the barrier isn't medicine; it's the insurance policy.

Learn More

Peer-reviewed literature

Liu X, et al. Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open. 2025.

Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists. JAMA. 2025.

Shahzad M, et al. GLP-1 Prescriptions for Weight Loss by Differences in Employer-Sponsored Insurance Coverage. JAMA Health Forum. 2026.

Sarpatwari A, et al. Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Patient Characteristics. JAMA Health Forum. 2025.

Pearson SD, et al. Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions. 2025.

Herges JR, et al. Navigating Cost and Access Barriers for Medications in the Treatment of Obesity. 2025.

American Medical Association. Private Insurance Coverage of Anti-Obesity Medications. Council on Medical Service. 2026.

Healthcare.gov. Internal and External Insurance Appeals.

Legal references

Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

Social Security Act §1927(d)(2).